Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse.

Next Previous
X
Search
Trial Profile

Open-Label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iodine I 131 derlotuximab biotin (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Oct 2011 Status changed from active, no longer recruiting to completed, according to a SIRO Clinpharm media release.
    • 07 Jun 2011 Interim results were presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
    • 19 May 2011 Interim results have been reported in a Peregrine Pharmaceuticals media release; additional results will be reported at ASCO-2011.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top